FDA warned Elite Health Center that its website falsely implied compounded semaglutide was FDA-approved, making the drugs misbranded.
What happened
FDA reviewed the website https://eliterapidfatloss.com in August 2025 and found it offered compounded drug products, including semaglutide. FDA said a website claim that compounded semaglutide was FDA-approved for obesity was false or misleading because compounded drugs are not FDA-approved. FDA called the products misbranded.
What FDA found
The website claimed compounded semaglutide was FDA-approved for obesity, which falsely implies the compounded products are the same as an FDA-approved drug.
FDCA § 502(a), 21 U.S.C. § 352(a); FDCA § 502(bb), 21 U.S.C. § 352(bb)Because of that false or misleading claim, FDA says the compounded semaglutide products are misbranded.
FDCA § 502(a), 21 U.S.C. § 352(a); FDCA § 502(bb), 21 U.S.C. § 352(bb)FDA says introducing or delivering the misbranded products into interstate commerce is prohibited.
FDCA § 301(a), 21 U.S.C. § 331(a)FDA also says receiving misbranded drugs in interstate commerce, or delivering or offering to deliver them, is a violation.
FDCA § 301(c), 21 U.S.C. § 331(c)
What FDA wants
FDA tells Elite Health Center to take immediate action, including ceasing and desisting from using the cited language, and to send a written response within 15 working days describing steps taken, how recurrence will be prevented, and related documentation.
Who should pay attention
- telehealth companies selling compounded semaglutide
- compounding pharmacies and their marketing partners
- clinics or brands that advertise compounded drugs as FDA-approved
This is a summary. Read the original letter on fda.gov.